Both Retail Investors Who Control a Good Portion of Humacyte, Inc. (NASDAQ:HUMA) Along With Institutions Must Be Dismayed After Last Week's 14% Decrease
Both Retail Investors Who Control a Good Portion of Humacyte, Inc. (NASDAQ:HUMA) Along With Institutions Must Be Dismayed After Last Week's 14% Decrease
Key Insights
關鍵見解
- Significant control over Humacyte by retail investors implies that the general public has more power to influence management and governance-related decisions
- The top 20 shareholders own 50% of the company
- Insiders have been buying lately
- 散戶投資者對Humacyte的嚴格控制意味着公衆擁有更大的影響管理和治理相關決策的權力
- 前20名股東擁有公司50%的股份
- 內部人士最近一直在買入
If you want to know who really controls Humacyte, Inc. (NASDAQ:HUMA), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are retail investors with 44% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
如果你想知道誰真正控制着Humacyte, Inc.(納斯達克股票代碼:HUMA),那麼你必須看看其股票登記處的構成。而持有最大份額的群體是擁有44%所有權的散戶投資者。換句話說,該集團面臨最大的上行潛力(或下行風險)。
While the holdings of retail investors took a hit after last week's 14% price drop, institutions with their 26% holdings also suffered.
儘管在上週股價下跌14%之後,散戶投資者的持股量受到打擊,但持有26%的機構也遭受了損失。
Let's delve deeper into each type of owner of Humacyte, beginning with the chart below.
讓我們從下圖開始,深入研究Humacyte的每種類型的所有者。
![1725106713732](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240831/43150280-0-f28029db4ed31572a912b6a2e6efbb20.webp/bigjpg)
What Does The Institutional Ownership Tell Us About Humacyte?
關於Humacyte,機構所有權告訴我們什麼?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
許多機構根據近似於當地市場的指數來衡量自己的表現。因此,他們通常會更多地關注主要指數中包含的公司。
We can see that Humacyte does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Humacyte's historic earnings and revenue below, but keep in mind there's always more to the story.
我們可以看到,Humacyte確實有機構投資者;他們持有公司很大一部分股票。這表明專業投資者有一定的信譽。但是我們不能僅僅依靠這一事實,因爲機構有時會像所有人一樣進行不良投資。當多家機構擁有一隻股票時,總是存在處於 「擁擠交易」 的風險。當這樣的交易出錯時,多方可能會競相快速出售股票。對於沒有增長曆史的公司,這種風險更高。你可以在下面看到Humacyte的歷史收益和收入,但請記住,故事總是有更多內容。
![1725106715028](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240831/43150280-1-27c12d150bc9bff2e76491c2b5e642d8.webp/bigjpg)
Hedge funds don't have many shares in Humacyte. Fresenius Medical Care AG is currently the company's largest shareholder with 15% of shares outstanding. Gavril Yushvaev is the second largest shareholder owning 7.5% of common stock, and BlackRock, Inc. holds about 6.0% of the company stock.
對沖基金在Humacyte的股票不多。費森尤斯醫療股份公司目前是該公司的最大股東,已發行股份的15%。加夫里爾·尤什瓦耶夫是第二大股東,擁有7.5%的普通股,貝萊德公司持有該公司約6.0%的股份。
A closer look at our ownership figures suggests that the top 20 shareholders have a combined ownership of 50% implying that no single shareholder has a majority.
仔細觀察我們的所有權數據就會發現,前20名股東的合併所有權爲50%,這意味着沒有一個單一股東擁有多數股東。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.
雖然研究公司的機構所有權數據是有意義的,但研究分析師的情緒以了解風向哪個方向吹來也是有意義的。有不少分析師報道了該股,因此你可以很容易地研究預測的增長。
Insider Ownership Of Humacyte
Humacyte的內部所有權
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
儘管內部人士的確切定義可能是主觀的,但幾乎每個人都認爲董事會成員是內部人士。公司管理層對董事會負責,後者應代表股東的利益。值得注意的是,有時高層管理人員自己也是董事會成員。
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
大多數人認爲內部所有權是積極的,因爲這可能表明董事會與其他股東關係良好。但是,在某些情況下,過多的權力集中在該群體中。
Our most recent data indicates that insiders own some shares in Humacyte, Inc.. In their own names, insiders own US$73m worth of stock in the US$734m company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.
我們最新的數據表明,內部人士擁有Humacyte, Inc.的部分股份。內部人士以自己的名義擁有這家價值7.34億美元的公司價值7300萬美元的股票。這至少顯示出一定的對齊性。你可以點擊這裏查看這些內部人士是否在買入或賣出。
General Public Ownership
一般公有制
The general public-- including retail investors -- own 44% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
包括散戶投資者在內的公衆擁有該公司44%的股份,因此不容忽視。這種所有權規模雖然可觀,但如果決定與其他大股東不同步,可能不足以改變公司的政策。
Private Company Ownership
私人公司所有權
We can see that Private Companies own 4.8%, of the shares on issue. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.
我們可以看到,私人公司擁有已發行股份的4.8%。可能值得對此進行更深入的研究。如果關聯方,例如內部人士,對其中一傢俬營公司有興趣,則應在年度報告中予以披露。私營公司也可能在公司中擁有戰略利益。
Public Company Ownership
上市公司所有權
It appears to us that public companies own 15% of Humacyte. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.
在我們看來,上市公司擁有Humacyte15%的股份。這可能是戰略利益,兩家公司可能有相關的商業利益。可能是他們已經消失了。這一裁定可能值得進一步調查。
Next Steps:
後續步驟:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 6 warning signs we've spotted with Humacyte (including 3 which are concerning) .
我覺得看看究竟誰擁有一家公司非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。爲此,你應該了解我們在Humacyte身上發現的6個警告信號(包括3個令人擔憂的警告信號)。
If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.
如果你想了解分析師對未來增長的預測,千萬不要錯過這份關於分析師預測的免費報告。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。